IEC-001 / Imvax - LARVOL DELTA

Imvax Presents New Data on Personalized Whole-Tumor Derived Immunotherapeutic Platform at 2022 International Cancer Immunotherapy Conference (Businesswire) - "The study was executed using IEC-001 (loaded with patient-derived endometrial cancer cells) or IGV-001 (loaded with patient-derived glioblastoma cells)...Results indicated that co-culture of PBMCs with the relevant Imvax candidate resulted in increased immunological activity of various types. These included, at various timepoints, increased dendritic cell maturation, elevated percentages of activated CD4+ and CD8+ T cells, increased effector memory CD4+ T cells, and T cell activation, responses that were further stimulated upon rechallenge. In summary, these results support the potential of Imvax's immunotherapeutic platform and further development of IEC-001 for the treatment of endometrial cancer."

Preclinical • Brain Cancer • CNS Tumor • Endometrial Cancer • Glioblastoma • Gynecologic Cancers • Oncology • Solid Tumor